Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2010.07.011PMID 20875764PMCID PMC2991632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contemporary Reviews in Cardiovascular Medicine Cardiovascular Magnetic Resonance

  2010cited by this paper
• Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

  2010cited by this paper
• A randomized study of alglucosidase alfa in late-onset Pompe's disease.

  2010cited by this paper
• New developments in the treatment of Pompe disease

  2010cited by this paper
• Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy.

  2009cited by this paper
• Images in Cardiovascular Medicine

  2009cited by this paper
• Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

  2009cited by this paper
• Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy.

  2009cited by this paper
• Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications.

  2009cited by this paper
• Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

  2008cited by this paper
• Fabry's disease presenting as ventricular tachycardia and left ventricular 'hypertrophy'.

  2008cited by this paper
• Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease

  2008cited by this paper
• Cardiac Remodeling After Enzyme Replacement Therapy with Acid α-Glucosidase for Infants with Pompe Disease

  2008cited by this paper
• Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

  2007cited by this paper
• Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

  2007cited by this paper
• Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.

  2007cited by this paper
• MRI characterization of myocardial tissue in patients with Fabry's disease.

  2007cited by this paper
• Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience

  2007cited by this paper
• Cardiac arrhythmias following anesthesia induction in infantile‐onset Pompe disease: a case series

  2007influential reference
• Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

  2007cited by this paper
• Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue.

  2007cited by this paper
• Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging.

  2006cited by this paper
• A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

  2006cited by this paper
• Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

  2006cited by this paper
• Electrocardiographic response to enzyme replacement therapy for Pompe disease

  2006cited by this paper
• The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.

  2006cited by this paper
• Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

  2006cited by this paper
• Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

  2006cited by this paper
• Cardiac magnetic resonance in myocardial disease

  2006cited by this paper
• Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

  2005cited by this paper
• Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

  2005cited by this paper
• Anaesthetic management of infants with glycogen storage disease type II: a physiological approach

  2004influential reference
• Pompe disease in infants and children.

  2004cited by this paper
• Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

  2003cited by this paper
• The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

  2003cited by this paper
• Rapid evaluation of right and left ventricular function and mass using real-time true-FISP cine MR imaging without breath-hold: comparison with segmented true-FISP cine MR imaging with breath-hold.

  2003cited by this paper
• How we perform delayed enhancement imaging.

  2003cited by this paper
• Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.

  2001cited by this paper
• Images in Cardiovascular Medicine

  2000cited by this paper
• Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging.

  1999cited by this paper
• A comparison of MRI and echocardiography in hypertrophic cardiomyopathy.

  1999cited by this paper
• Echocardiography in Pediatric Heart Disease.

  1998cited by this paper
• Echocardiography in Pediatric Heart Disease

  1990cited by this paper
• A Retrospective

  1988cited by this paper
• Estimation of human myocardial mass with MR imaging.

  1988cited by this paper
• Cardiovascular Magnetic Resonance with the Use of Delayed Enhancement Improved Detection of Coronary Artery Disease by Stress Perfusion

  year unknowncited by this paper

• Infantile-onset Pompe disease entering adulthood: insights from two decades of enzyme replacement therapy experience.

  2025cites this paper
• Cardiovascular Computed Tomography and Magnetic Resonance Imaging Guideline of the Brazilian Society of Cardiology and the Brazilian College of Radiology - 2024.

  2024cites this paper
• Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis

  2024cites this paper
• Cardiac magnetic resonance of hypertrophic heart phenotype: A review

  2023cites this paper
• Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies

  2022cites this paper
• Prognostic factors in hypertrophic cardiomyopathy in children: An MRI based study.

  2022cites this paper
• Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies

  2021cites this paper
• The Role of MRI in Prognostic Stratification of Cardiomyopathies

  2020cites this paper
• Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the "Working Group on myocardial and pericardial diseases" of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. European Heart

  2018cites this paper
• Scientific Documents Committee (2017). Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the "Working Group on myocardial and pericardial diseases" of the European Society of Cardiology Endorsed

  2018cites this paper
• Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography

  2017cites this paper
• Pompe disease, a storage cardiomyopathy

  2017cites this paper
• Left ventricular mass and systolic function in children with chronic kidney disease—comparing echocardiography with cardiac magnetic resonance imaging

  2016cites this paper
• Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population.

  2016cites this paper
• Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel

  2016cites this paper
• Delayed Myocardial Enhancement in Cardiac Magnetic Resonance Imaging.

  2015cites this paper
• Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease

  2015cites this paper
• Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVI

  2015cites this paper
• Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVI.

  2015cites this paper
• Non-coding RNAs as direct and indirect modulators of epigenetic mechanism regulation of cardiac fibrosis

  2015cites this paper
• The Emerging Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Metabolic Cardiomyopathies

  2015cites this paper
• Consenso argentino para el diagnóstico, seguimiento y tratamiento de la enfermedad de Pompe

  2014cites this paper
• The Right Ventricle

  2012cites this paper
• Unusual cardiac "masses" in a newborn with infantile pompe disease.

  2012cites this paper
• New imaging modalities to assess cardiac function: not just pretty pictures

  2012cites this paper
• The emerging phenotype of long-term survivors with infantile Pompe disease

  2012cites this paper
• Assessing disease severity in Pompe disease: The roles of a urinary glucose tetrasaccharide biomarker and imaging techniques

  2012cites this paper
• Cardiac Pathology in Glycogen Storage Disease Type III.

  2012cites this paper
• Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy.

  2011cites this paper
• Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy.

  2009cites this paper